Pharmacoresistance in Epilepsy

<p>Chapter 1. Why study Drug Resistant Epilepsy?</p><p>Luisa Rocha, Esper Cavalheiro and Alberto Lazarowski.</p><p><br></p><p>Chapter 2. Pharmacoresistance in Epilepsy</p><p>Daniel San-Juan and Roberto Antonio Cordova Peralta.</p><p><br></p><p>Chapter 3. Experimental models for the study of drug-resistant epilepsy.</p><p>Monserrat Fuentes-Mejia, Angeles Nuñez-Lumbreras, Christopher Martínez-Aguirre, Luisa Rocha.</p><p><br></p><p>Chapter 4. On Complexity and Emergence: Linking the Hypotheses of Pharmacoresistance in Epilepsy&nbsp;&nbsp;</p><p>Gabriel Servilha-Menezes, Alan Talevi and Norberto Garcia-Cairasco.</p><p><br></p><p>Chapter 5. Role of High-Frequency Oscillation Networks in Managing Pharmacoresistant Epilepsy</p>Shennan Aibel Weiss and Richard Staba.<p></p><p><br></p><p>Chapter 6. Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?</p><p>Liliana Czornyj, Jerónimo Auzmendi and Alberto Lazarowski.</p><p><br></p><p>Chapter 7. Changes in Targets as an Explanation for Drug Resistance in Epilepsy&nbsp;</p><p>Christopher Martínez-Aguirre, Daniel Fonseca-Barriendos, Saúl Huerta de la Cruz, Monserrat Fuentes-Mejía, and Luisa Rocha.</p><p><br></p><p>Chapter 8. Cellular and molecular mechanisms of neuroinflammation in drug-resistant epilepsy.</p><p>Octavio Fabián Mercado-Gómez, Virginia Selene Arriaga-Ávila, Angélica Vega-García, Josué Sánchez-Hernández, Adriana Jiménez, Diana Organista-Juárez, Mara A. Guzmán-Ruiz and Rosalinda Guevara-Guzmán.</p><p><br></p><p>Chapter 9. Contribution of the antiepileptic drug administration regime to avoid the development and/or establishment of pharmacoresistant epilepsy.</p><p>Pietro Fagiolino and Marta Vázquez</p><p><br></p><p>Chapter 10. Pharmacogenetics in Epilepsy and Refractory Epilepsy.</p><p>Liliana Czornyj, Jerónimo Auzmendi and Alberto Lazarowski</p><p><br></p><p>Chapter 11. Seizures Induce Hypoxia or Hypoxia Induces Seizures. A Perverse Relationship that Increases the Risk of SUDEP.</p><p>Jerónimo Auzmendi and Alberto Lazarowski.</p><p><br></p><p>Chapter 12. Neonatal excitotoxicity triggers degenerative processes related to seizure susceptibility and pharmacoresistance.</p><p>Mónica E. Ureña-Guerrero, Antoni Camins-Espuny and Carlos Beas-Zárate.</p><p><br></p><p>Chapter 13. Cerebrovascular remodeling and the role of vascular endothelial growth factor in the epileptic brain and pharmacoresistance.</p><p>José Luis Castañeda-Cabral, Mónica E. Ureña-Guerrero, and Silvia Josefina López-Pérez.</p><p><br></p><p>Chapter 14. The Role of JNK3 in Epilepsy and Neurodegeneration.</p><p>Ester Verdaguer, Rubén D. Castro-Torres, Jordi Olloquequi, Jesús Ureña, Miren Ettcheto, Antoni Parcerisas, Antoni Camins and Carme Auladell.</p><p><br></p><p>Chapter 15. Application of proteomics in the study of molecular markers in epilepsy.</p><p>Maria José da Silva Fernandes, Andressa Sampaio Pereira, Constanza Catalina Paz Rocha Jaures, Mariana Baldini Prudencio and Daniele Suzete Persike.</p><p><br></p><p>Chapter 16. GABAergic neurotransmission abnormalities in pharmacoresistant epilepsy: experimental and human studies.</p><p>Sandra Orozco-Suárez, Iris Angélica Feria-Romero, Mónica Elisa Ureña-Guerrero, Luisa Rocha, Mario A. Alonso-Vanegas.</p><p>    </p><p>Chapter 17. Genes involved in pharmacoresistant epilepsy.</p><p>Iris E. Martínez-Juárez, Diego A. Barrios-González, Aurelio Jara Prado, Fernando Sotelo-Díaz, Juan A. Calderón Martínez, Georgina J. Mejía del Castillo, Patricia J. Morales Chinga, Adriana Ochoa, Antonio V. Delgado-Escueta.</p><p><br></p><p>Chapter 18. Drug-resistant Epilepsy and the Influence of Age, Gender and Comorbid Disorders.&nbsp;</p><p>Jesús Servando Medel-Matus, César E. Santana-Gómez, Ángel Alberto Puig-Lagunes.</p><p><br></p>Chapter 19. Indications for Intracerebral Recording in Candidates for Epilepsy Surgery<p></p><p>Silvia Oddo, Brenda Giagante and Silvia Kochen.</p><p><br></p><p>Chapter 20. On the Development of New Drugs for the Treatment of Drug Resistant Epilepsy: An Update on Different Approaches to Different Hypotheses.</p><p>Alan Talevi.</p><p><br></p><p>Chapter 21. Physical exercise as a strategy to reduce seizure susceptibility.</p><p>Ricardo Mario Arida.</p><p>Chapter 22. Ketogenic Diet and Drug-resistant Epilepsy.</p><p>Roberto Caraballo.</p><p><br></p><p>Chapter 23. Modulating P-glycoprotein Regulation as a Therapeutic Strategy for Pharmacoresistant Epilepsy.</p><p>Daniel Perez-Perez, Hiram Luna-Munguia, Heidrun Potschka.</p><br><p></p><p>Chapter 24. Vagus Nerve Stimulation for Intractable Seizures.</p><p>Mario A. Alonso Vanegas.</p><p><br></p><p>Chapter 25. Non Invasive Brain Stimulation as a potential Therapeutic Procedure in drug-resistant epilepsy</p><p>Lilia Morales Chacón and Lazaro Gomez Fernandez.</p><p><br></p>Chapter 26. Effects of transcranial focal electrical stimulation via concentric ring electrodes on seizure activity.&nbsp;<p></p><p>Walter G. Besio.</p>